Megan R. Haymart, MD, is an Associate Professor of Medicine at the University of Michigan with a primary appointment in the Division of Metabolism, Endocrinology, and Diabetes and a secondary appointment in the Division of Hematology/Oncology. Dr. Haymart's research focuses on variation in the management of thyroid cancer with an emphasis on the role of patients, providers, and health systems in thyroid cancer diagnosis and treatment. She also studies thyroid cancer outcomes and the rise in thyroid cancer incidence. She is Principal Investigator of the NCI-funded R01 grant “Treatment Decision Making in Low-Risk Thyroid Cancer” and the AHRQ-funded R01 grant “Imaging Practices and Overdiagnosis of Thyroid Cancer”.
Dr. Haymart received her medical degree from Johns Hopkins University School of Medicine in 2002, completed internal medicine residency at Johns Hopkins Hospital in 2005, and then completed fellowship in endocrinology, diabetes and metabolism at the University of Wisconsin in 2007. In 2009, she joined the University of Michigan faculty as Assistant Professor of Medicine and in 2017 she was promoted to Associate Professor of Medicine. Dr. Haymart is involved in creating the National Comprehensive Cancer Network thyroid carcinoma guidelines, is on the Board of Directors for the American Thyroid Association, serves on the editorial board for the Journal of Clinical Oncology, and is Associate Editor for Thyroid.
Treatment Decision Making in Low-Risk Thyroid Cancer - R01 CA201198 - 7/15/16-6/30/20 - NIH/NCI - The major goal is to determine the role of physician and
patient perceptions, including both knowledge and attitude, in thyroid cancer treatment decision making. These results will serve as the foundation for the creation of tailored educational interventions to personalize care for thyroid cancer patients. Role: Principal Investigator
Imaging Practices and Overdiagnosis of Thyroid Cancer - R01 HS024512-01AI - 9/30/16 – 7/30/20 - AHRQ - The major goal is to clarify the relationship between imaging, both thyroid targeted and imaging associated with incidental cancer discovery, and the rise in thyroid cancer incidence. These findings will be used to develop a clinical strategy to minimize the overdiagnosis of thyroid cancer and to serve as a model for overdiagnosis in general. Role: Principal Investigator
Haymart MR, Banerjee M, Stewart AK, Koenig RJ, Birkmeyer JD, Griggs JJ. Use of radioactive iodine for thyroid cancer. JAMA, 2011;306(7):721-728. PMCID: PMC3352591
Haymart MR, Banerjee M, Yang D*, Stewart AK, Koenig RJ, Griggs JJ. The role of clinicians in determining radioactive iodine use for low-risk thyroid cancer. Cancer, 2013;119(2): 259-265. PMCID: PMC3465617
Schuessler KM*, Banerjee M, Yang D*, Stewart AK, Doherty GM, Haymart MR. Surgeon training and use of radioactive iodine for stage I thyroid cancer patients. Annals of Surgical Oncology,2013;20(3):733-738. PMCID: PMC3667416
Papaleontiou M*, Banerjee M, Yang D*, Sisson J, Koenig R, Haymart MR. Factors that influence radioactive iodine use for thyroid cancer. Thyroid, 2013;23(2):219-224. PMCID: PMC3569922
Haymart MR, Muenz D*, Stewart AK, Griggs JJ, Banerjee M. Disease severity and radioactive iodine use for thyroid cancer. Journal of Clinical Endocrinology and Metabolism, 2013;98(2):678-686. PMCID: PMC3565122
Haymart MR, Banerjee M, Yang D*, Stewart AK, Griggs JJ, Sisson JC, Koenig RJ. Referral patterns for patients with high-risk thyroid cancer. Endocrine Practice, 013;19(4):638-43. PMCID:PMC3747229
Haymart MR, Banerjee M, Yang D*, Stewart AK, Sisson JC, Koenig RJ, Doherty GM, Griggs JJ. Variation in the management of thyroid cancer. Journal of Clinical Endocrinology and Metabolism, 2013;98(5):2001-8. PMCID: PMC3644603
Chandrasekhar SS, Randolph GW, Seidman MD, Rosenfeld RM, Angelos P, Barkmeier-Kraemer J, Benninger MS, Blumin JH, Dennis G, Hanks J, Haymart MR, Kloos RT, Seals B, Schreibstein JM, Thomas MA, Waddington C, Warren B, Robertson PJ; American Academy of Otolaryngology-Head and Neck Surgery. Clinical practice guideline: improving voice outcomes after thyroid surgery. Otolaryngology Head Neck Surgery, 2013;148(6 Suppl):S1-37. PMCID: Not required
Haymart MR, Banerjee M, Yin H, Worden F, Griggs JJ. Marginal Treatment Benefit in Anaplastic Thyroid Cancer. Cancer, 2013;119(17):3133-9. PMCID: PMC4038063
Haymart MR, Banerjee M, Yang D*, Stewart AK, Doherty GM, Koenig RJ, Griggs JJ. The relationship between extent of thyroid cancer surgery and use of radioactive
iodine. Annals of Surgery, 2013;258(2):354-8. PMCID: PMC3708979
Esfandiari NH, Hughes DT, Yin H, Banerjee M, Haymart MR. The effect of extent of surgery and number of lymph node metastases on overall survival in patients with medullary thyroid cancer. Journal of Clinical Endocrinology and Metabolism, 2014;99(2):448-54. PMCID: PMC3913800
Banerjee M, Muenz DG*, Chang JT*, Papaleontiou M*, Haymart M. Tree-Based Model for Thyroid Cancer Prognostication. Journal of Clinical Endocrinology and Metabolism,
2014;99(10):3737-45. PMCID: PMC4184064
Banerjee M, Muenz DG*, Worden F, Wong SL, Haymart MR. Conditional Survival in Patients with Thyroid Cancer. Thyroid, 2014;24(12):1784-9. PMCID: PMC4267546
Tuttle RM, Haddad RI, Ball DW, Byrd D, Dickson P, Duh QY, Ehya H, Haymart M, Hoh C, Hunt JP, Iagaru A, Kandeel F, Kopp P, Lamonica DM, Lydiatt WM, McCaffrey J, Moley
JF, Parks L, Raeburn CD, Ridge JA, Ringel MD, Scheri RP, Shah JP, Sherman SI, Sturgeon C, Waguespack SG, Wang TN, Wirth LJ, Hoffmann KG, Hughes M. Thyroid
carcinoma, version 2.2014. J Natl Compr Canc Netw., 2014;12(12):1671-80. PMC journal -- in process
Wiebel JL*, Banerjee M, Muenz DG*, Worden FP, Haymart MR. Trends in Imaging After Diagnosis of Thyroid Cancer. Cancer, 2015;121(9):1387-94. PMCID: PMC4409471
Davies L, Morris LG, Haymart M, Chen AY, Goldenberg D, Morris J, Ogilvie JB, Terris DJ, Netterville J, Wong RJ, Randoph G. American Association of Clinical Endocrinologists and American College of Endocrinology Disease State Clinical Review: The Increasing Incidence of Thyroid Cancer. Endocrine Practice, 2015;21:686-96.
Wiebel JL*, Esfandiari NH, Papaleontiou M*, Worden FP, Haymart MR. Evaluating Positron Emission Tomography Use in Differentiated Thyroid Cancer. Thyroid, 2015;25(9):1026-32. PMCID: PMC4560853
Haddad RI, Lydiatt WM, Ball DW, Busaidy NL, Byrd D, Callender G, Dickson P, Duh QY, Ehya H, Haymart M, at al. NCCN Anaplastic Thyroid Carcinoma Version 2, Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network, 2015;13(9):1140-50.
Banerjee M, Wiebel JL*, Guo C*, Gay B, Haymart MR. Use of imaging tests after primary treatment of thyroid cancer in the United States: Population based retrospective cohort study evaluating death and recurrence. BMJ, 2016;354:i3839.
Papaleontiou M*, Haymart MR. Inappropriate use of suppressive doses of thyroid hormone in thyroid nodule management: Results from a nationwide survey. Endocr Pract., 2016; 22(11):1358-1360.
Haymart MR, Pearce EN. How much should thyroid cancer impact plans for pregnancy? Thyroid. 2017; 27(3):312-314
Choksi P, Papaleontiou M*, Guo C*, Worden F, Banerjee M, Haymart MR. Skeletal complications and mortality in thyroid cancer: A population-based study. Journal of Clinical Endocrinology and Metabolism, 2017;102(4):1254-1260.
Papaleontiou M*, Hughes DT, Guo C, Banerjee M, Haymart MR. Population-based assessment of complications following surgery for thyroid cancer. Journal of Clinical Endocrinology and Metabolism, 2017 Apr 28 [Epub ahead of print]
Papaleontiou M*, Gauger PG, Haymart MR. Referral of older thyroid cancer patients to a high-volume surgeon: Results of a multidisciplinary physician survey. Endocrine Practice, 2017 May 23 [Epub ahead of print].